Lakefront Biotherapeutics (LKFT) Assets (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Assets data on file, last reported at $3.9 billion in Q1 2026.

• Assets for Q1 2026 came in at $3.9 billion, down 6.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.9 billion (down 6.67% YoY), and the FY2025 annual result was $4.0 billion, down 10.27% from the prior year.
• Assets held at $3.9 billion in Q1 2026 per LKFT's latest filing, from $4.0 billion in the prior quarter.
• Over five years, Assets peaked at $5.7 billion in Q1 2022 and troughed at $3.9 billion in Q1 2026.
• A 5-year average of $4.6 billion and a median of $4.6 billion in 2024 frame the typical range for Assets.
• The sharpest annual moves came in 2022 and 2023: Assets dropped 18.69% in 2022, then slipped 2.94% in 2023.
• A 5-year view of Assets shows it stood at $4.8 billion in 2022, then declined by 2.94% to $4.7 billion in 2023, then declined by 5.74% to $4.4 billion in 2024, then decreased by 10.27% to $4.0 billion in 2025, then decreased by 0.43% to $3.9 billion in 2026.
• Business Quant data shows LKFT's Assets at $3.9 billion in Q1 2026, $4.0 billion in Q4 2025, and $4.1 billion in Q3 2025.